Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiamet G is a potent, highly selective, and cell-permeable small molecule inhibitor of O-GlcNAcase (OGA), the enzyme responsible for removing O-linked N-acetylglucosamine (O-GlcNAc) modifications from nucleocytoplasmic proteins. By inhibiting OGA, Thiamet G increases the global levels of O-GlcNAcylation on various proteins, which can modulate their stability, localization, and activity. It is widely used as a pharmacological tool in research to study the role of O-GlcNAc signaling in diverse biological processes, including neurodegeneration (e.g., Alzheimer's disease), metabolism, and reproductive biology. In the context of ovarian tissue research, it has been used to demonstrate that hyper-O-GlcNAcylation can destabilize transcription factors like FOXL2, leading to reduced estrogen synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamet G.